Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab.

Kawashima Y, Nishikawa S, Ninomiya H, Yoshida R, Takano N, Oguri T, Kitazono S, Yanagitani N, Horiike A, Ohyanagi F, Ishikawa Y, Nishio M.

Intern Med. 2019;58(10):1479-1484. doi: 10.2169/internalmedicine.1673-18. Epub 2019 May 15.

2.

Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017.

Takano N, Ariyasu R, Koyama J, Sonoda T, Saiki M, Kawashima Y, Oguri T, Hisakane K, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Ohyanagi F, Horiike A, Gemma A, Nishio M.

Lung Cancer. 2019 May;131:69-77. doi: 10.1016/j.lungcan.2019.03.008. Epub 2019 Mar 21.

PMID:
31027701
3.

Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer.

Nokihara H, Nishio M, Yamamoto N, Fujiwara Y, Horinouchi H, Kanda S, Horiike A, Ohyanagi F, Yanagitani N, Nguyen L, Yaron Y, Borgman A, Tamura T.

Clin Lung Cancer. 2019 May;20(3):e317-e328. doi: 10.1016/j.cllc.2018.12.018. Epub 2018 Dec 31.

4.

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.

Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Calleja EM, Nishio M.

Mol Cancer Ther. 2019 Mar;18(3):531-540. doi: 10.1158/1535-7163.MCT-18-0831. Epub 2019 Jan 24.

PMID:
30679388
5.

A dose-finding randomized Phase II study of oral netupitant in combination with palonosetron .75 mg intravenous for the prevention of chemotherapy-induced nausea and vomiting in Japanese patients receiving highly emetogenic chemotherapy.

Osaki A, Inoue K, Sakai H, Yamada K, Minato K, Ohyanagi F, Tokuda Y, Ikeda N, Kagamu H, Kubota K, Tamura T, Saeki T.

Jpn J Clin Oncol. 2019 Feb 1;49(2):121-129. doi: 10.1093/jjco/hyy161.

PMID:
30576544
6.

Rapid Progression of Lung Cancer Following Emergency Caesarean Section Led to Postpartum Acute Respiratory Failure.

Watanabe T, Yamashita T, Sugawara H, Fukuchi T, Ishii A, Nagai Y, Ohyanagi F, Koyama S, Ushijima J, Takagi K, Tanaka A.

Intern Med. 2019 Apr 1;58(7):991-997. doi: 10.2169/internalmedicine.1105-18. Epub 2018 Nov 19.

7.

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer.

Sonoda T, Nishikawa S, Sakakibara R, Saiki M, Ariyasu R, Koyama J, Kitazono S, Yanagitani N, Horiike A, Ohyanagi F, Ninomiya H, Ishikawa Y, Nishio M.

Respir Med Case Rep. 2018 Mar 16;24:19-21. doi: 10.1016/j.rmcr.2018.03.009. eCollection 2018.

8.

Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer.

Saiki M, Kitazono S, Yoshizawa T, Dotsu Y, Ariyasu R, Koyama J, Sonoda T, Uchibori K, Nishikawa S, Yanagitani N, Horiike A, Ohyanagi F, Oikado K, Ninomiya H, Takeuchi K, Ishikawa Y, Nishio M.

Clin Lung Cancer. 2018 Sep;19(5):435-440.e1. doi: 10.1016/j.cllc.2018.04.006. Epub 2018 May 10.

PMID:
29885946
9.

A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.

Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N.

Int J Clin Oncol. 2018 Apr;23(2):382-388. doi: 10.1007/s10147-017-1200-4. Epub 2017 Oct 16.

PMID:
29039073
10.

Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene.

Saiki M, Ohyanagi F, Ariyasu R, Koyama J, Sonoda T, Nishikawa S, Kitazono S, Yanagitani N, Horiike A, Ninomiya H, Ishikawa Y, Nishio M.

Jpn J Clin Oncol. 2017 Dec 1;47(12):1189-1192. doi: 10.1093/jjco/hyx133.

PMID:
28977547
11.

Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib.

Ariyasu R, Horiike A, Koyama J, Saiki M, Sonoda T, Kawashima Y, Takano N, Oguri T, Nishikawa S, Kitazono S, Yanagitani N, Ohyanagi F, Nishio M.

Anticancer Drugs. 2017 Jun;28(5):565-567. doi: 10.1097/CAD.0000000000000489.

PMID:
28225456
12.

Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.

Iwama E, Sakai K, Azuma K, Harada T, Harada D, Nosaki K, Hotta K, Ohyanagi F, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.

Ann Oncol. 2017 Jan 1;28(1):136-141. doi: 10.1093/annonc/mdw531.

PMID:
28177428
13.

EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer.

Sakakibara R, Inamura K, Tambo Y, Ninomiya H, Kitazono S, Yanagitani N, Horiike A, Ohyanagi F, Matsuura Y, Nakao M, Mun M, Okumura S, Inase N, Nishio M, Motoi N, Ishikawa Y.

Clin Lung Cancer. 2017 Sep;18(5):527-534.e1. doi: 10.1016/j.cllc.2016.12.002. Epub 2016 Dec 22.

PMID:
28111119
14.

A case treated with nivolumab after small cell lung cancer transformation of mutant EGFR non-small cell lung cancer.

Nishikawa S, Tambo Y, Ninomiya H, Oguri T, Kawashima Y, Takano N, Kitazono S, Ohyanagi F, Horiike A, Yanagitani N, Ishikawa Y, Nishio M.

Ann Oncol. 2016 Dec;27(12):2300-2302. doi: 10.1093/annonc/mdw431. Epub 2016 Oct 19. No abstract available.

PMID:
27760736
15.

Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study.

Suzuki K, Yamanaka T, Hashimoto H, Shimada Y, Arata K, Matsui R, Goto K, Takiguchi T, Ohyanagi F, Kogure Y, Nogami N, Nakao M, Takeda K, Azuma K, Nagase S, Hayashi T, Fujiwara K, Shimada T, Seki N, Yamamoto N.

Ann Oncol. 2016 Aug;27(8):1601-6. doi: 10.1093/annonc/mdw220. Epub 2016 Jun 29.

PMID:
27358385
16.

Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.

Horiike A, Takeuchi K, Uenami T, Kawano Y, Tanimoto A, Kaburaki K, Tambo Y, Kudo K, Yanagitani N, Ohyanagi F, Motoi N, Ishikawa Y, Horai T, Nishio M.

Lung Cancer. 2016 Mar;93:43-6. doi: 10.1016/j.lungcan.2015.12.011. Epub 2015 Dec 30.

PMID:
26898613
17.

Prognostic significance of CpG island methylator phenotype in surgically resected small cell lung carcinoma.

Saito Y, Nagae G, Motoi N, Miyauchi E, Ninomiya H, Uehara H, Mun M, Okumura S, Ohyanagi F, Nishio M, Satoh Y, Aburatani H, Ishikawa Y.

Cancer Sci. 2016 Mar;107(3):320-5. doi: 10.1111/cas.12876. Epub 2016 Feb 19.

18.

Distinct Characteristics of Small Cell Lung Cancer Correlate With Central or Peripheral Origin: Subtyping Based on Location and Expression of Transcription Factor TTF-1.

Miyauchi E, Motoi N, Ono H, Ninomiya H, Ohyanagi F, Nishio M, Okumura S, Ichinose M, Ishikawa Y.

Medicine (Baltimore). 2015 Dec;94(51):e2324. doi: 10.1097/MD.0000000000002324.

19.

Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer.

Saga T, Inubushi M, Koizumi M, Yoshikawa K, Zhang MR, Tanimoto K, Horiike A, Yanagitani N, Ohyanagi F, Nishio M.

Cancer Sci. 2015 Nov;106(11):1554-60. doi: 10.1111/cas.12771. Epub 2015 Oct 7.

20.

Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer.

Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T.

Invest New Drugs. 2015 Jun;33(3):632-40. doi: 10.1007/s10637-015-0227-5. Epub 2015 Mar 18.

PMID:
25777467
21.

Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation.

Tanaka H, Horiike A, Sakatani T, Saito R, Yanagitani N, Kudo K, Ohyanagi F, Horai T, Nishio M.

Anticancer Drugs. 2015 Jun;26(5):573-8. doi: 10.1097/CAD.0000000000000220.

PMID:
25714250
22.

A double-blind randomized Phase II study of olanzapine 10 mg versus 5 mg for emesis induced by highly emetogenic chemotherapy.

Nagashima K, Iwasa S, Yanai T, Hashimoto H, Suzuki K, Ohyanagi F, Shimada Y, Yamamoto N.

Jpn J Clin Oncol. 2015 Feb;45(2):229-31. doi: 10.1093/jjco/hyu191. Epub 2014 Nov 14.

PMID:
25398581
23.

Phase II study of docetaxel-plus-bevacizumab combination therapy in patients previously treated for advanced non-squamous non-small cell lung cancer.

Ohyanagi F, Yanagitani N, Kudo K, Kawano Y, Sakatani T, Tanimoto A, Nishizawa H, Horiike A, Hagiwara S, Horai T, Nishio M.

Anticancer Res. 2014 Sep;34(9):5153-8.

PMID:
25202107
24.

A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).

Horinouchi H, Yamamoto N, Nokihara H, Horai T, Nishio M, Ohyanagi F, Horiike A, Nakagawa K, Terashima M, Okabe T, Kaneda H, McKee MD, Carlson DM, Xiong H, Tamura T.

Cancer Chemother Pharmacol. 2014 Jul;74(1):37-43. doi: 10.1007/s00280-014-2478-9. Epub 2014 May 8.

PMID:
24807459
25.

Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.

Horiike A, Yamamoto N, Tanaka H, Yanagitani N, Kudo K, Ohyanagi F, Ono A, Naito T, Murakami H, Horai T, Nishio M.

Anticancer Res. 2014 Apr;34(4):1975-81.

PMID:
24692734
26.

A phase II study of S-1 in relapsed small cell lung cancer.

Kudo K, Ohyanagi F, Horiike A, Miyauchi E, Tahanaka H, Yanagitani N, Saito R, Kaburaki K, Sakatani T, Horai T, Nishio M.

Mol Clin Oncol. 2013 Mar;1(2):263-266. Epub 2013 Jan 14.

27.

A feasibility study of carboplatin plus irinotecan treatment for elderly patients with extensive disease small-cell lung cancer.

Misumi Y, Nishio M, Takahashi T, Ohyanagi F, Horiike A, Murakami H, Kenmotsu H, Yamamoto N, Ishii M, Shimokawa T, Hida N, Okamoto H.

Jpn J Clin Oncol. 2014 Feb;44(2):116-21. doi: 10.1093/jjco/hyt195. Epub 2013 Dec 13.

PMID:
24338555
28.

Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study.

Kawano Y, Ohyanagi F, Yanagitani N, Kudo K, Horiike A, Tanimoto A, Nishizawa H, Ichikawa A, Sakatani T, Nakatomi K, Hagiwara S, Ninomiya H, Motoi N, Ishikawa Y, Horai T, Nishio M.

Anticancer Res. 2013 Aug;33(8):3327-33. Erratum in: Anticancer Res. 2013 Sep;33(9):4137.

PMID:
23898099
29.

Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.

Sakai K, Horiike A, Irwin DL, Kudo K, Fujita Y, Tanimoto A, Sakatani T, Saito R, Kaburaki K, Yanagitani N, Ohyanagi F, Nishio M, Nishio K.

Cancer Sci. 2013 Sep;104(9):1198-204. doi: 10.1111/cas.12211. Epub 2013 Jul 1.

30.

Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer.

Harada H, Nishio M, Murakami H, Ohyanagi F, Kozuka T, Ishikura S, Naito T, Kaira K, Takahashi T, Horiike A, Nishimura T, Yamamoto N.

Clin Lung Cancer. 2013 Jul;14(4):440-5. doi: 10.1016/j.cllc.2013.01.003. Epub 2013 Mar 27.

PMID:
23540866
31.

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.

Horiike A, Kudo K, Miyauchi E, Ohyanagi F, Kasahara K, Horai T, Nishio M.

Br J Cancer. 2011 Oct 11;105(8):1131-6. doi: 10.1038/bjc.2011.375. Epub 2011 Sep 13.

32.

[A case of adenocarcinoma of the lung with a pulmonary thromboembolism which improved with gefitinib].

Yanagitani N, Horiike A, Kudo K, Ohyanagi F, Nishio M, Horai T.

Nihon Kokyuki Gakkai Zasshi. 2011 Apr;49(4):282-6. Japanese.

PMID:
21591457
33.

Clinicopathological findings of non-small-cell lung cancer with high serum progastrin-releasing peptide concentrations.

Kudo K, Ohyanagi F, Horiike A, Miyauchi E, Yanagitani N, Hoshi R, Satoh Y, Motoi N, Hamanaka W, Ishikawa Y, Mun M, Sakao Y, Okumura S, Nakagawa K, Horai T, Nishio M.

Lung Cancer. 2011 Dec;74(3):401-4. doi: 10.1016/j.lungcan.2011.03.019. Epub 2011 Apr 29.

PMID:
21529988
34.

Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study.

Ohyanagi F, Horai T, Sekine I, Yamamoto N, Nakagawa K, Nishio M, Senger S, Morsli N, Tamura T.

Jpn J Clin Oncol. 2011 May;41(5):718-22. doi: 10.1093/jjco/hyr021. Epub 2011 Mar 9.

PMID:
21393255
35.

Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.

Ohyanagi F, Yamamoto N, Horiike A, Harada H, Kozuka T, Murakami H, Gomi K, Takahashi T, Morota M, Nishimura T, Endo M, Nakamura Y, Tsuya A, Horai T, Nishio M.

Br J Cancer. 2009 Jul 21;101(2):225-31. doi: 10.1038/sj.bjc.6605152.

36.

Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer.

Horiike A, Kimura H, Nishio K, Ohyanagi F, Satoh Y, Okumura S, Ishikawa Y, Nakagawa K, Horai T, Nishio M.

Chest. 2007 Jun;131(6):1628-34.

PMID:
17565015
37.

Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer.

Ohyanagi F, Horiike A, Okano Y, Satoh Y, Okumura S, Ishikawa Y, Nakagawa K, Horai T, Nishio M.

Cancer Chemother Pharmacol. 2008 Mar;61(3):503-8. Epub 2007 May 5.

PMID:
17483949
38.

Gefitinib efficacy associated with multiple expression of HER family in non-small cell lung cancer.

Nishio M, Taguchi F, Ohyanagi F, Horikike A, Ishikawa Y, Satoh Y, Okumura S, Nakagawa K, Nishio K, Horai T.

Anticancer Res. 2006 Sep-Oct;26(5B):3761-5.

39.

Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.

Ohyanagi F, Taguchi F, Horai T, Kasahara K, Takeda Y, Shibata K, Shirosaki H, Nishio M.

Jpn J Clin Oncol. 2006 Sep;36(9):547-51. Epub 2006 Jul 26.

PMID:
16870693
40.

Postoperative ischemic change in bronchial stumps after primary lung cancer resection.

Satoh Y, Okumura S, Nakagawa K, Horiike A, Ohyanagi F, Nishio M, Horai T, Ishikawa Y.

Eur J Cardiothorac Surg. 2006 Jul;30(1):172-6. Epub 2006 May 26.

PMID:
16730184
41.

Antipyrine test predicts pharmacodynamics in docetaxel and cisplatin combination chemotherapy.

Nishio M, Matsuda M, Ohyanagi F, Sato Y, Okumura S, Tabata D, Morikawa A, Nakagawa K, Horai T.

Lung Cancer. 2005 Aug;49(2):245-51.

PMID:
16022919
42.

Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients.

Nishio M, Ohyanagi F, Horiike A, Ishikawa Y, Satoh Y, Okumura S, Nakagawa K, Nishio K, Horai T.

Br J Cancer. 2005 May 23;92(10):1877-80.

43.

Phase I study of combination chemotherapy with gemcitabine and irinotecan for non-small cell lung cancer.

Nishio M, Ohyanagi F, Taguch F, Matsuda M, Sato Y, Okumura S, Nakagawa K, Horai T.

Lung Cancer. 2005 Apr;48(1):115-9.

PMID:
15777978
44.

Acute gefitinib-induced pneumonitis.

Ohyanagi F, Ando Y, Nagashima F, Narabayashi M, Sasaki Y.

Int J Clin Oncol. 2004 Oct;9(5):406-9.

PMID:
15549594
45.

Re: Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

Ando Y, Ohtsu T, Ando M, Ohyanagi F, Nagashima F, Narabayashi M, Saijo N, Sasaki Y.

J Natl Cancer Inst. 2003 Nov 5;95(21):1638-40. No abstract available.

PMID:
14600098

Supplemental Content

Loading ...
Support Center